Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Developing technologies to engineer plant genomes at the megabase scale (OMEGA)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Integrative B iology : from Genes and Genomes to S ystems
Panel description: For all organis ms: Genetics, epigenetics, genomics  and other ‘omics studies , bioinformatics, systems biology , genetic diseases , gene editing, innovative methods and modelling,  ‘omics for personalised  medicine
Countries involved: Belgium
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-07-01
End date: 2027-06-30
Duration (months): 60.0
Total project cost (EUR): 1496250.0
EU funding (EUR): 1496250.0
Participants: 1
Project status: SIGNED

Genomics research combined with revolutionary genome editing tools has created new opportunities to explore fundamental aspects of biology and develop novel (bio)technologies for medicine, agriculture, and industry. The OMEGA project is designed to build on these developments by enabling Megabase-scale engineering of plant genomes. Experimentally-determined lists of essential genes have been crucial for such large-scale projects in other species but are currently unavailable in plants. Therefore, the OMEGA project needs to determine which plant genes are essential for growth and development. However, the standard technologies used to identify essential genes are limited by genetic interactions (e.g. redundancy, synthetic lethality). My group is developing multiplex CRISPR screens in plants to specifically overcome these limitations. The OMEGA project will use this capability to identify genome-wide essential genes and genetic interactions in Physcomitrium patens. This will be the first systematic genetic interaction screen in plants and will likely identify interactions conserved across the green lineage. The OMEGA project will also develop technologies to move, edit, and delete DNA at the Megabase scale. As proof-of-concept, I aim to reduce ~10% of the P. patens genome and remove all non-essential DNA from one chromosome. The SCRaMbLE system will be adapted for P. patens and used as an alternative approach to minimize chromosomes and also perform in planta directed evolution. Lastly, we will use a DNA assembly method developed in my lab to build biosynthetic pathways in vivo using modular DNA assembly methods. These tools will create opportunities to explore fundamental aspects of genomics, chromosomal biology and synthetic biology. The objectives of project OMEGA are necessarily ambitious as these technologies will allow us to perform controlled, Megabase-scale engineering projects in plant genomes not possible with the current generation of genome editing tools.

Keywords: genetic interactions,essential genes,crispr screens
The Mediterranean as a Laboratory of Globalisation: The Franco-Ottoman Cloth Trade, 1683-c.1715 (GlobalMed)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Netherlands
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-09-01
End date: 2025-08-31
Duration (months): 24.0
Total project cost (EUR): 187624.32
EU funding (EUR): 187624.32
Participants: 1
Project status: CLOSED

In the early 1700s, France overcame English and Dutch competition to become the Ottoman Empire’s main European trading partner. To date, historians have focussed on Jean-Baptiste Colbert, Louis XIV’s (in)famous minister, and his influence on the crucial Franco-Ottoman trade in woollen cloth. Yet they have neglected the boom in this trade after Colbert’s death in 1683, overseen by Jean-Baptiste de Lagny, the director general of commerce from 1686 to 1700. By treating the Mediterranean as a laboratory of globalisation, GlobalMed asks why this trade flourished. Moreover, it explores the trade’s significance in influencing the state’s global commercial policy, analysing how France’s Levantine success shaped its engagement with (non-)colonial markets overseas. In this way, the project will challenge current orthodoxies on the rise of the Atlantic world by reconsidering the early modern state’s role as a motor of globalisation and industrial development.

Keywords: french history,ottoman history,mediterranean history,chartered companies,cloth,industry,economic development,state intervention,networks,agency
Biocatalytic membranes for micro/nano plastic degradation within waste water effluents (BMRex)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain,Denmark,Germany,Portugal,United Kingdom
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-04-01
End date: 2027-03-31
Duration (months): 48.0
Total project cost (EUR): 3638501.25
EU funding (EUR): 3638501.0
Participants: 10
Project status: SIGNED

The universal use of different types of plastic-based materials as new products to meet the insatiable global demands of the 20th century has had an unprecedented impact on our evolution as a society. Unfortunately, micro- and nano-plastics are now ubiquitous in marine and freshwater environments, as well as terrestrial ecosystems, where they act as a source of highly detrimental toxic chemicals that negatively affect the environment and human health by interacting with terrestrial organisms that mediate ecosystem services and functions, such as soil dwelling invertebrates, terrestrial fungi and plant pollinators. It is our duty as scientists to provide immediate and appropriate solutions to control the fate and reduce the effects of micro/nano-plastics on our planet. BMRex will develop entirely new concepts for micro/nano-plastic removal from household and industrial waste water effluents by validating a novel biocatalyst-based membrane reactor technology to degrade plastic waste avoiding further damage. The consortium will produce, test & optimize biocatalytic membrane reactors based on porous inorganic scaffolds functionalized with ionic liquid materials modified for biofouling resistance, plastic affinity and controlled attachment of plastic-degrading enzymes. Interchangeable enzyme species will permit a precise control of stepwise catalytic processes enhanced with artificial cytosis, maximizing activity and stability of the biocatalytic reactions. BMRex will also evaluate the economic and technological viability of this novel technology. With its unique integration of scientific approaches, competences and resources, BMRex has the potential to open up an entirely new technological field. In the long term, this project aims to enable an in situ, more efficient and safer recycling of waste waters with transformative effects on a society that is currently in the very early phases of transitioning toward an environmentally sustainable use of plastic.

Keywords: plastic degrading enzymes,polyoxometalate,hybrid materials,biocatalysis,ceramics,ionic liquids
The first universal and price-neutral insulin pen (GO-Pen)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Denmark
Call: EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2023-03-01
End date: 2025-08-31
Duration (months): 30.0
Total project cost (EUR): 4642308.75
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

The challenge for many people with diabetes (PwD) is that they don’t get the right dose of insulin at the right time. This can potentially give long term health issues, and even shorten their lifetime. Today, this is an everyday challenge for more than 13 million people that still inject insulin with a 100 year’s old outdated technology (syringes and needles) and cannot afford branded insulin and modern pens. GO-Pen ApS developed the 1st affordable, safe, and sustainable insulin injection system that fits the unmet health needs in the world’s most resource constrained population. The UNIPEN system innovation relies on the possibility of refilling a disposable cartridge with any kind of insulin available, resulting in a cost-competitive device to syringes solution improving the accuracy. Now, with the support of the EIC-A funding, we intend to refine the design of the UNIPEN device, demonstrate its design and clinical usability, and fine-tune the scale-up production.
Next generation MSCA: opening a new era for change (MSCA2022)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: MSCA other
Action type: Coordination and support actions
Countries involved: France
Call: Presidency event: MSCA Conference under French Presidency (HORIZON-MSCA-2021-FRC-IBA, 2021)
Start date: 2022-04-01
End date: 2022-09-30
Duration (months): 6.0
Total project cost (EUR): 150000.25
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

France will take over the rotating EU Council Presidency in the first half of 2022. On behalf of the French Ministry for Higher Education, Research, and Innovation, Université Paris Sciences et Lettres – PSL, will organize the 2022 “Marie-Skłodowska-Curie Actions (MSCA) Presidency Conference”. In the spirit of previous conferences, this conference will highlight the achievements and future of the MSCA programme, the European Union’s flagship funding programme for training, mobility and career development of researchers. 2022 is a crucial year for the future of higher education and research in Europe : it marks the launch of Horizon Europe and the organization of the first Conference of the Future of Europe. It is also 25 years since the MSCA programme was launched. Over 25 years, Marie Skłodowska-Curie Actions fostered excellence in research by bringing together a European community of researchers and supporting their careers at all stages. Moreover, far from being disconnected from society, the MSCA programme has also been a driver of change by supporting, for instance, closer links between science and citizens as well as advancing careers for female researchers. How has MSCA helped advance research and innovation in Europe for the past 25 years? What are the key societal challenges that the MSCA programme should help further address for its next 25 years? Based on these questions, this 2022 MSCA conference will be entitled "Next generation MSCA: opening a new era for change”. The conference will be an opportunity to take stock on the transformational achievements of the MSCA programme and reflect upon what a “future-proof” and inclusive MSCA would be. Mostly organized at the Institut Curie, the idea is to offer a hybrid event, accessible both in person and remotely.

Keywords: msca presidency conference,pfue,challenges,next generation
VISIOWELL : a high-throughput imaging device for non-adherent cells (VisioWell)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2025-POC, 2025)
Start date: 2026-02-01
End date: 2027-07-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 2
Project status: SIGNED

Measuring single cell dynamics (cell division and death) is crucial to understand organism development, tissue regeneration, immune response, cancer development, response to treatment. For example, it can identify if a treatment induces cell death or a block in division on a given cells during drug screening. Ex-vivo single cell live-cell imaging can unlock the single cell dynamics analysis for translational research. Unfortunately, no options are commercially available for the study of non-adherent cells (immune cells, blood cells and progenitors, sperm cells, oocytes or circulating cancer cells). This hampers drug screening and bioengineering, affecting the development of novel therapies. The main requirements are high throughput to analyse thousands of single cell in parallel and efficient automated image data analysis. Moreover, this type of analysis requires specialists in biology, image analysis and data science. With VisioWell, we will develop the first accessible solution for ex-vivo single cell live-cell imaging on motile cells. VisioWell is an end-to-end tool, conceived specifically for motile cells and developed for non-specialists in microfabrication and imaging analysis. It leverages microfabrication and machine learning, allowing complex experimental designs with simple lab equipment (e.g. imaging platform or a microscope for live-cell protocols). To establish the potential of VisioWell, we will perform two testbeds, covering drug screening and clinical sample analysis. We will distribute this device through partnerships with academic and industrial stakeholders.VisioWell can unlock the potential of ex vivo single cell live-cell imaging for non-specialists. Access to this method will advance research and development for translational purposes.
PERSONALIZED IN VITRO CULTURED LIMBAL STEM CELL THERAPY TO CURE CORNEAL BLINDNESS - LIMBUSTEM PRO AMEX (Limbustem PRO AMEX)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Türkiye
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2450000.0
EU funding (EUR): 2450000.0
Participants: 1
Project status: SIGNED

Limbal Stem Cell Deficiency (LSCD), a serious medical condition, leads to corneal blindness that cannot be treated with corneal transplantation. LSCD is caused by the loss of limbal stem cells, which are critical for the regeneration and maintenance of the corneal epithelium. In many conditions, such as chemical ocular burns, these stem cells are irreversibly affected. The loss of these cells causes the recess of corneal epithelium renewal and eventually conjunctivalization of the corneal surface. Without the stem cells, the cornea becomes opaque and vascularized, leading to blindness. LSCD affects ≈ 1 in 2000 people, translating to ≈ 375,000 patients in Europe alone. This number increases by ≈ 1,800 new cases, annually. Further, as 30% of the total patients are not suitable for the conventional treatment options, ≈ 100,000 patients in only Europe are lack of any treatment option. In addition, ≈ 500 new cases are added to this number, annually. LSCD is classified as an orphan disease, which means it affects a relatively small percentage of the population but has a significant impact on those affected. The global cell therapy market size was estimated at € 13.30 billion in 2023 and is expected to reach € 89 billion by 2033 with CAGR of 22.66% from 2024 to 2033. Limbustem has developed an advanced cell therapy for treating LSCD by improving in vitro cultivated limbal stem cell transplantation. Our innovation involves using amnion membrane extract (AME) as a supplement in the cell culture media, which has increased the stem cell content from 50% to 70% in preclinical studies. The next step is to confirm these promising results with clinical trials to enhance the product's clinical success rate. With the gradual increase in the number of centres and patients, it will reach an annual turnover of €30 million in 5 years. It is expected that the product will reach a pre-tax profitability of ≈ 50% of the sales and have a positive cash flow from the first year.

Keywords: ocular surface,corneal blindness,limbal stem cell deficiency,cellular therapy product
Disruptive plasma process enabling plastic waste and CO2 recycling, replacing natural gas in the chemical industry (PlasTecRecycling)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Cyclize enables the defossilization of the chemical industry by producing and offering fully circular, electric, and cost-competitive syngas. Syngas, a mix of hydrogen and carbon monoxide, is already used to make plastics, solvents, and fuels. Today, it is mostly produced from coal or natural gas as both an energy and carbon source. Cyclize has developed a groundbreaking syngas production technology that uses mixed plastic waste that cannot be recycled otherwise and CO2 as a carbon source, with electricity for energy. This is made possible through our two-step heat integrated process of pyrolysis and plasma reforming. Our novel plasma technology is the key innovation for high efficiency. The world demand for syngas today is 421 billion cubic meters per year, creating a potential huge impact. Scaling and commercializing our technology to meet this enormous demand is the goal of this funding application. In light of the abundance of plastic waste and the chemical industry’s move away from fossil carbon, our product can disrupt the world syngas market and help establish resource independence in Europe. We operate a demo plant at the University of Stuttgart and we plan the development of a larger plant at a chemical park with a capacity of 2.3 million cubic meters per year and increase the capacity further to 7 million cubic meters – the first commercially relevant scaling step.

Keywords: plasma,waste to syngas,carbon recycling,dry and steam reforming,defossilization,gasification,circular economy
Revolutionizing remote care of chronic disease patients – an interoperable and smart monitoring platform (HumanITcare)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Spain
Call: Strategic Digital and Health Technologies (HORIZON-EIC-2021-ACCELERATORCHALLENGES-01, 2021)
Start date: 2022-07-01
End date: 2025-06-30
Duration (months): 36.0
Total project cost (EUR): 3592250.0
EU funding (EUR): 2438800.0
Participants: 1
Project status: CLOSED

The growing demand for proper monitoring and treatment of chronic disease patients is unsustainable for European healthcare systems. Despite the recent advancements, remote patient monitoring (RPM) systems have not achieved their potential due their inability to integrate accurate data from any given medical device to the Electronic Health Records (EHRs). To cater to the urgent need of innovative monitoring systems, we deliver the HumanITcare platform; an AI-powered platform which can collect data from any given device, adapt itself for the needs of the patients and enables integration into the EHRs. HumanITcare reduces 40% of total visits and generates smart alarms and reports to inform patients and caregivers, hence contributing significantly to clinical and self-care. With our innovative software architecture, we enable security, interoperability, sustainability and scalability. The superior features of our platform will enable us to be the leaders of the industry in Europe.

Keywords: sustainable healthcare,interoperability,heart failure,remote patient monitoring,home care,chronic diseases,cloud computing,neural networks,machine learning,digital health
On-the-move Schengen border control using extended EUDI wallet, smartphone and external sensor technologies (OnMoveID)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Border Management
Action type: Innovation actions
Countries involved: Slovenia,Czechia,Germany,Austria,France,Poland,United Kingdom,Finland,Slovakia,Estonia,Croatia,Spain
Call: Advanced user-friendly, compatible, secure identity and travel document management (HORIZON-CL3-2024-BM-01, 2024)
Start date: 2025-09-01
End date: 2028-08-31
Duration (months): 36.0
Total project cost (EUR): 6826947.51
EU funding (EUR): 5706640.59
Participants: 15
Project status: SIGNED

OnMoveID will leverage increasing sensory, computational and communicational technological capabilities of standard non-trusted smartphones for advanced privacy-preserving, legal and ethical compliant management of travel documents for fast on-the-move identification of travellers for all types of border crossings: land, sea, and air. High efficiency and security are achieved in three phases: (1) Registration of border crossing (duration ca. 10 min only once, then e.g. annually), within trusted extended 3rd generation EUID wallet. Also, self-scanned identity documents will be stored, verified and used to assess biometric standstill face images and fingerprints using smartphone cameras. (2) Back-up registration (duration ca. 5 min) at registration desk at border with advanced document scanning and digital identity generation using AI. (3.1) Walk-through along lanes (duration ca. 20 sec) of travellers is used to identify and track in consent smartphone positions using ultrasound, to conduct body count from heart beat detection and localization, to generate external best face images from multiple fixed (multi)spectral cameras, while using smartphone sensors to take walk-through face and fingerprint images. (3.2) Drive-through passenger vehicles (ca. 10 sec) uses multispectral cameras. (3.3) Bus inspection (duration ca. 2 min) uses in addition smartphone camera of border officers for taking in-consent images of passengers within the bus. OnMoveID will use rule- and risk-based decision making to accept (back-up) registration as well as final border crossing acceptance or rejection. It extends S-o-t-A of all existing legacy and emerging border management systems and data bases (e.g. EES, VIS, ETIAS) at EU level while improving travellers’ throughput, based on communication and cloud computing within extended EUID/digital wallet framework. OnMoveID is functionally and performance tested and iteratively improved at borders in (i) Finland, (ii) Slovakia, and (iii) UK.

Keywords: on the move border crossing extending entry exit system ees on the move person identification verified credentials for person identification border crossings on the airports,seaports,land